IL2 and neoplasm: The authors argue that the combination of PD-L1 knockdown siRNA and immunostimulatory pDNA/IL-2 delivered using LNPs reduces the drug resistance rate and leads to enhanced anti-tumor activity while also providing tumor-selective therapeutic properties [166].